Palvella Therapeutics (PVLA) Payables (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Payables data on file, last reported at $5.4 million in Q1 2026.

• On a quarterly basis, Payables fell 15.2% year-over-year to $5.4 million in Q1 2026; TTM through Mar 2026 was $5.4 million, a 15.2% decrease from a year earlier, with the FY2025 full-year figure at $6.8 million, up 3.46% from the prior year.
• Payables for Q1 2026 stood at $5.4 million, down from $6.8 million in the prior quarter.
• Over the last five years, Payables for PVLA reached as high as $7.6 million in Q2 2023 and fell as low as $801000.0 in Q3 2024.
• Historically, Payables has averaged $4.2 million across 5 years, with a median of $4.5 million in 2022.
• Across the five-year window, Payables plunged 87.26% in 2024 and soared 611.24% in 2025, its largest moves.
• Year by year, Payables stood at $4.2 million in 2022, then plunged by 77.47% to $936000.0 in 2023, then jumped by 601.28% to $6.6 million in 2024, then increased by 3.46% to $6.8 million in 2025, then dropped by 19.85% to $5.4 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $5.4 million in Q1 2026, $6.8 million in Q4 2025, and $5.7 million in Q3 2025.